Fentanyl Half-Life by Route of Administration
The elimination half-life of fentanyl varies substantially by route: IV fentanyl has a terminal half-life of 3–12 hours (typically 7 hours), transdermal fentanyl demonstrates an apparent half-life of 17–27 hours after patch removal due to continued skin absorption, and sublingual fentanyl formulations have been discontinued as of September 2024. 1, 2, 3
Intravenous Fentanyl Half-Life
The terminal elimination half-life after IV administration ranges from 3 to 12 hours, with a typical value of approximately 7 hours in surgical patients. 1, 2
One study of constant-rate IV infusion reported elimination half-lives of 7.3–9.7 hours in postoperative patients. 4
The FDA label specifies that after IV administration, fentanyl has an apparent half-life of approximately 7 hours (range 3–12 hours) in most patient populations. 1
In hepatically impaired patients, the half-life may extend to 4–12 hours, though clearance shows marked variability (3–80 L/hr). 1, 2
Volume of distribution is 6 L/kg (range 3–8 L/kg), and fentanyl accumulates in skeletal muscle and fat, being released slowly back into circulation. 1
Transdermal Fentanyl Half-Life
After removal of a transdermal patch, serum fentanyl concentrations decline with an apparent half-life of approximately 17 hours (range 13–22 hours), which is substantially longer than IV administration. 1
The FDA label for transdermal fentanyl states that serum concentrations fall about 50% in approximately 20–27 hours after patch removal. 2
This prolonged apparent half-life is not due to slower drug elimination but rather to continued absorption from a cutaneous depot of fentanyl that concentrates in the upper skin layers during patch application. 1, 5
One pharmacokinetic study found a terminal half-life of 17.0 ± 2.3 hours after transdermal system removal, compared to 6.1 ± 2.0 hours after IV administration in the same patients. 5
At the time of patch removal, approximately 1.07 ± 0.43 mg of fentanyl remains in the cutaneous depot, continuing to be absorbed systemically. 5
Clinical reviews report terminal half-lives of 13–25 hours for transdermal fentanyl, with the prolonged offset creating potential safety concerns if adverse effects develop. 6, 7
Clinical Implications of Transdermal Pharmacokinetics
Serum concentrations reach plateau 12–24 hours after initial patch application and remain relatively constant for the 72-hour wearing period. 1, 2
Steady-state is achieved by the end of the second 72-hour patch application (approximately 6 days of continuous use). 1, 2
The NCCN guideline recommends decreasing basal opioid infusions by 50% at 6 hours after patch placement, then stopping at 12 hours, or alternatively stopping the infusion at 6 hours. 3
Because of continued absorption after patch removal, adverse effects including respiratory depression do not resolve immediately and may require naloxone infusion for up to 24 hours. 6
Sublingual Fentanyl Status
As of September 30,2024, all transmucosal immediate-release fentanyl medications (including sublingual formulations) have been discontinued in the United States. 3
The NCCN guideline now recommends using concentrated oral morphine solution (20 mg/mL) or oral oxycodone solution (20 mg/mL) for sublingual administration as alternatives for breakthrough pain. 3
Prior to discontinuation, sublingual/buccal fentanyl formulations were used for breakthrough pain, though evidence did not demonstrate clear superiority over other immediate-release opioids. 8
Context-Sensitive Half-Life: Remifentanil Comparison
For context, remifentanil (an ultra-short-acting fentanyl analog) has a context-sensitive half-life of only 3–4 minutes regardless of infusion duration, due to metabolism by plasma esterases rather than hepatic pathways. 9
This contrasts sharply with fentanyl's context-sensitive half-life of approximately 200 minutes (≈6 hours) after a 3-hour infusion, increasing to 300 minutes (≈12 hours) after longer infusions. 9
Special Population Considerations
Elderly patients may have reduced clearance and prolonged half-life of fentanyl, though specific values are not provided in FDA labeling. 2
Renal impairment does not significantly alter fentanyl half-life because fentanyl lacks neurotoxic active metabolites and is primarily hepatically metabolized; clearance ranges 30–78 L/hr in renally impaired patients. 1, 2
In hepatic impairment, half-life may range from 4–12 hours with highly variable clearance (3–80 L/hr), warranting cautious dosing and extended intervals. 1, 2